X4 Pharmaceuticals, Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that X4 Pharmaceuticals, Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.50M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.60M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Mar 17, 2026 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.11M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.56M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $0 | Mar 26, 2025 |
| FY2022 | Dec 31, 2021 | $0 | Mar 21, 2023 |
| FY2022 | Dec 31, 2020 | $3.00M | Mar 21, 2023 |
| FY2021 | Dec 31, 2019 | $0 | Mar 17, 2022 |
| FY2018 | Dec 31, 2018 | $3.50M | Mar 11, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($79.20M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($37.45M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | ($101.17M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | ($93.87M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | ($88.70M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | ($62.13M) | Mar 21, 2023 |
| FY2021 | Dec 31, 2019 | ($52.81M) | Mar 17, 2022 |
| FY2018 | Dec 31, 2018 | ($9.36M) | Mar 11, 2019 |
| FY2018 | Sep 30, 2018 | ($10.90M) | Mar 11, 2019 |
| FY2018 | Jun 30, 2018 | ($12.13M) | Mar 11, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($86.88M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($36.40M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | ($107.52M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | ($87.57M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | ($85.11M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | ($59.87M) | Mar 21, 2023 |
| FY2021 | Dec 31, 2019 | ($51.70M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2018 | ($29.09M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2017 | ($22.25M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | ($24.35M) | Mar 11, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.72M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $81.64M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $72.02M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $61.06M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $50.65M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | $41.93M | Mar 21, 2023 |
| FY2021 | Dec 31, 2019 | $30.16M | Mar 17, 2022 |
| FY2020 | Dec 31, 2018 | $20.35M | Mar 19, 2021 |
| FY2019 | Dec 31, 2017 | $17.07M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $17.83M | Mar 11, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($85.62M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($130.90M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | ($96.51M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | ($77.10M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | ($70.91M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | ($58.82M) | Mar 21, 2023 |
| FY2021 | Dec 31, 2019 | ($48.06M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2018 | ($25.42M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2017 | ($21.31M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | ($21.64M) | Mar 11, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $326.0K | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | $60.0K | Mar 26, 2025 |
| FY2024 | Dec 31, 2022 | $103.0K | Mar 26, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $290.46M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $146.45M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $147.26M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $155.59M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $117.18M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $122.87M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $160.70M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $9.94M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $81.25M | Mar 11, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.17M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $124.30M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $96.16M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $81.54M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $52.76M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $50.07M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $31.48M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $21.62M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $22.55M | Mar 11, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $186.29M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $22.15M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $51.10M | Mar 17, 2026 |
| FY2025 | Dec 31, 2022 | $74.05M | Mar 17, 2026 |
| FY2024 | Dec 31, 2021 | $64.41M | Mar 26, 2025 |
| FY2023 | Dec 31, 2020 | $72.80M | Mar 21, 2024 |
| FY2022 | Dec 31, 2019 | $129.22M | Mar 21, 2023 |
| FY2021 | Dec 31, 2018 | ($77.09M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2017 | ($44.55M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2016 | ($23.05M) | Mar 12, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.35M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $17.35M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $17.35M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $17.35M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $17.35M | Mar 21, 2024 |
| FY2023 | Dec 31, 2020 | $27.11M | Mar 21, 2024 |
| FY2020 | Dec 31, 2019 | $27.11M | Mar 19, 2021 |
| FY2019 | Mar 13, 2019 | $27.10M | Mar 12, 2020 |
| FY2019 | Dec 31, 2018 | $0 | Mar 12, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($594.55M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($515.36M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($477.91M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($376.74M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($282.87M) | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | ($194.18M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($132.04M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | ($79.24M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($92.27M) | Mar 11, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $217.05M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $55.70M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $99.22M | Mar 26, 2025 |
| FY2024 | Dec 31, 2022 | $121.72M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $81.79M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | $78.71M | Mar 21, 2023 |
| FY2021 | Dec 31, 2019 | $126.18M | Mar 17, 2022 |
| FY2021 | Dec 31, 2018 | $8.13M | Mar 17, 2022 |
| FY2020 | Dec 31, 2017 | $26.68M | Mar 19, 2021 |
| FY2019 | Dec 31, 2016 | $15.16M | Mar 12, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.00M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $75.00M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $55.00M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $32.50M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $32.50M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $32.50M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $20.00M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $10.00M | Mar 12, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | (17) | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Mar 21, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | (17) | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Mar 21, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 90.91M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 5.70M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 167.43M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | 121.67M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 28.13M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | 16.31M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 16.13M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | 351,652 | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 14.29M | Mar 11, 2019 |